Belvedere Trading
TCRT icon

Belvedere Trading’s Alaunos Therapeutics TCRT Stock Holding History

Belvedere Trading’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-99
Closed -$9.32K – 1122
2023
Q1 		$9.32K Sell
99
-522
-84% -$49.7K ﹤0.01% 760
2022
Q4 		$60.4K Buy
+621
New +$90K ﹤0.01% 591

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's TCRT Position: Q2 2023 in Review

Belvedere Trading sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 99 shares — an estimated $9.32K sold.

Belvedere Trading first reported a position in TCRT in Q3 2022 and held it in 3 quarters. The position peaked at $78K in Q3 2022. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Belvedere Trading reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 99 Alaunos Therapeutics shares in Q2 2023, an estimated $9.32K.
  • Belvedere Trading first reported a position in Alaunos Therapeutics in Q3 2022 and held it in 3 quarters.
  • Belvedere Trading's Alaunos Therapeutics position peaked at $78K in Q3 2022.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.